Recombinant Human Chemokine (C-C Motif) Ligand 22, His-tagged

• Cat.No.: CCL22-112H
• Product Overview: Recombinant human CCL22/MDC, fused to His-tag at N-terminus, was expressed as insoluble protein aggregate inE.coliand purified by conventional chromatography, after refolding of the isolated inclusion bodies in a renaturation buffer. MW =10.3 kDa (90aa).

Specification

• Cat. No.: CCL22-112H
• Description: CCL22/MDC is a small cytokine belonging to the CC chemokine family.This protien displays chemotactic activity for natural killer cells, chronically activated T lymphocytes, monocytes and dendritic cells. It interacts with cell surface chemokine receptors CCR4. This chemokine may play a role in the trafficking of activated T lymphocytes to inflammatory sites and other aspects of activated T lymphocyte physiology.
• Source: E.coli.
• Amino Acid Sequence: MGSSHHHHHH SSGLVPRGSH MGPYGANMED SVCCRDYVRY RLPLRVVKHF YWTSDSCPRP GVVLLTFRDK EICADPRVPW VKMILNKLSQ
• Form: Liquid. In phosphate-buffered Saline(PBS) pH7.4, 10% glycerol.
• Purity: > 95% by SDS – PAGE.
• Concentration: 0.5 mg/ml (determined by Bradford assay).
• Endotoxin Level: < 1.0 EU per 1 μg of protein (determined by LAL method).
• Storage: Can be stored at +4°C short term (1-2 weeks). For long term storage, aliquot and store at -20°C or -70°C. Avoid repeated freezing and thawing cycles.

Gene Information

• Gene Name: CCL22 chemokine (C-C motif) ligand 22 [ Homo sapiens ]
• Synonyms: CCL22; chemokine (C-C motif) ligand 22; MDC; ABCD-1; SCYA22; STCP-1; DC/B-CK; MGC34554; A-152E5.1; small inducible cytokine A22; CC chemokine STCP-1; macrophage-derived chemokine; stimulated T cell chemotactic protein 1; small inducible cytokine subfamily A (Cys-Cys), member 22; Macrophage-derived chemokine; Small-inducible cytokine A22; Stimulated T-cell chemotactic protein 1; MDC(1-69)
• Gene ID: 6367
• mRNA Refseq: NM_002990
• Protein Refseq: NP_002981
• MIM: 602957
• UniProt ID: O00626
• Chromosome Location: 16q13
• Pathway: Chemokine signaling pathway; Cytokine-cytokine receptor interaction
• Function: chemokine activity

Reviews

05/01/2022

The catalytic activity of CCL22 is very strong, which can significantly improve the selectivity and yield of chemical reactions, and has high application value.

03/13/2022

This repeatability of CCL22 is very good, which can ensure the safety of the experiment and avoid unnecessary risks.

08/25/2019

CCL22 were well suited for our research needs due to their simple storage conditions and long-term preservation.

Q&As

What are the gene expression regulatory mechanisms of CCL22 protein?

The expression of CCL22 gene is regulated by a variety of signaling pathways, including inflammatory factor-mediated signaling pathways, cytokine-mediated signaling pathways, and transcription factors.

What is the potential application value of CCL22 protein in treatment?

Studies have shown that by interfering with the interaction of the CCL22 protein and its receptor CCR4, tumor growth, improve inflammatory response, and regulate autoimmune diseases can be inhibited. These findings provide potential application value for the development of corresponding therapeutic strategies.

Are there inhibitors or antagonists that interact with the CCL22 protein?

A number of inhibitors or antagonists that interact with CCL22 proteins have been developed that block the binding of CCL22 to its receptor CCR4, thereby interfering with its biological function.

How to study the mechanism of action of CCL22 protein in specific diseases?

The mechanism of action of CCL22 protein in specific diseases can be studied through cell culture experiments, animal models, clinical samples, and related biochemical techniques.

How does the CCL22 protein relate to other chemokines?

There are complex interactions between CCL22 proteins and other chemokines. They may influence the migration and localization of immune cells by competing for receptors, mutual regulation of expression, etc.

What is the role of CCL22 protein in tumor immunotherapy?

Some studies have shown that in tumor immunotherapy, inhibiting the expression of CCL22 or interfering with its interaction with CCR4 can enhance the effect of immunotherapy and improve the survival rate of patients.